Moody Lynn & Lieberson’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-113,836
Closed -$16.6M 227
2017
Q3
$16.6M Buy
113,836
+49,978
+78% +$6.81M 2.02% 14
2017
Q2
$8.29M Sell
63,858
-35,210
-36% -$4.31M 1.09% 34
2017
Q1
$12.3M Buy
99,068
+3,684
+4% +$441K 1.73% 15
2016
Q4
$11M Buy
95,384
+34,907
+58% +$3.89M 1.59% 20
2016
Q3
$6.32M Buy
60,477
+15,496
+34% +$1.68M 1.05% 37
2016
Q2
$4.44M Sell
44,981
-34,290
-43% -$3.55M 0.79% 44
2016
Q1
$7.93M Sell
79,271
-66,104
-45% -$6.81M 1.25% 30
2015
Q4
$17.4M Buy
145,375
+2,458
+2% +$284K 2.74% 6
2015
Q3
$15.5M Sell
142,917
-7,180
-5% -$891K 2.97% 4
2015
Q2
$17.4M Sell
150,097
-11,285
-7% -$1.29M 2.76% 5
2015
Q1
$18.6M Sell
161,382
-8,913
-5% -$1.07M 2.97% 6
2014
Q4
$19M Buy
170,295
+2,368
+1% +$250K 2.72% 5
2014
Q3
$15.9M Buy
167,927
+40,804
+32% +$3.68M 2.37% 9
2014
Q2
$10.9M Sell
127,123
-20,631
-14% -$1.57M 1.5% 21
2014
Q1
$10.3M Sell
147,754
-9,422
-6% -$746K 1.49% 17
2013
Q4
$13.3M Sell
157,176
-16,078
-9% -$1.27M 1.81% 8
2013
Q3
$13.4M Buy
173,254
+9,594
+6% +$672K 2.06% 4
2013
Q2
$9.57M Buy
+163,660
New +$9.85M 1.67% 16

Other funds holding CELG

Moody Lynn & Lieberson's CELG Position: Q4 2017 in Review

Moody Lynn & Lieberson sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 113,836 shares — an estimated $16.6M sold.

Moody Lynn & Lieberson first reported a position in CELG in Q2 2013 and held it in 18 quarters. The position peaked at $19M in Q4 2014. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Moody Lynn & Lieberson reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Moody Lynn & Lieberson sold 113,836 Celgene Corp shares in Q4 2017, an estimated $16.6M.
  • Moody Lynn & Lieberson first reported a position in Celgene Corp in Q2 2013 and held it in 18 quarters.
  • Moody Lynn & Lieberson's Celgene Corp position peaked at $19M in Q4 2014.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Moody Lynn & Lieberson's 13F filing for Q4 2017, filed 2 Feb 2018.